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The principal projection neurons of the striatum are critically dependent on an afferent
supply of brain derived neurotrophic factor (BDNF) for neurotrophic support. These
neurons express TrkB, the cognate receptor for BDNF, which activates signaling
pathways associated with neuronal survival and phenotypic maintenance. Impairment
of the BDNF-TrkB pathway is suspected to underlie the early dysfunction and prominent
degeneration of striatal neurons in Huntington disease (HD). Some studies in HD models
indicate that BDNF supply is reduced, while others suggest that TrkB signaling is
impaired earlier in disease progression. It remains important to determine whether a
primary defect in TrkB signaling underlies reduced neurotrophic support and the early
vulnerability of striatal neurons in HD. Using the transgenic R6/2 mouse model of HD we
found that prior to striatal degeneration there are early deficits in striatal protein levels of
activated phospho-TrkB and the downstream-regulated protein DARPP-32. In contrast,
total-TrkB and BDNF protein levels remained normal. Primary neurons cultured from
R6/2 striatum exhibited reduced survival in response to exogenous BDNF applications.
Moreover, BDNF activation of phospho-TrkB and downstream signal transduction was
attenuated in R6/2 striatal cultures. These results suggest that neurotrophic support of
striatal neurons is attenuated early in disease progression due to defects in TrkB signal
transduction in the R6/2 model of HD.
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INTRODUCTION
Huntington’s disease (HD) is a progressive autosomal dominant disease characterized by
early hyperkinetic movements and behavioral changes (Roze et al., 2011). HD patients
carry an expanded CAG-repeat in exon 1 of the IT15/HTT gene that yields an elongated
polyglutamine stretch in the N-terminal domain of the huntingtin (htt) protein (Bates, 2005).
Abbreviations: BDNF, brain-derived neurotrophic factor; DARPP-32, dopamine- and cAMP-regulated neuronal
phosphoprotein 32 kDa; Erk1/2, extracellular signal-regulated kinase 1/2; htt, huntingtin; HD, Huntington disease;
MSNs, medium spiny neurons.
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A hallmark of HD is the early degeneration of medium spiny
neurons (MSNs) in the striatum, which constitute >95% of the
neuronal population in the striatum. MSNs are the principal
projection neurons of the striatum, which is the initial relay
nucleus of the basal ganglia network that processes cortical and
thalamic glutamatergic and midbrain dopaminergic signals that
regulate locomotor and motivational behavior (Tepper et al.,
2007). In HD patients and animal models mutant huntingtin
(mhtt) is expressed by a wide variety of neuronal populations
with no clear preference for the vulnerable MSNs population
(Trottier et al., 1995; Bhide et al., 1996). Therefore the early
degeneration of MSNs in HD may be related to striatum-
specific cellular processes that are sensitive to the presence
of mhtt. Evidence in cellular and animal models of HD and
in HD (Raymond et al., 2011; Francelle et al., 2014) indicate
mhtt expression is associated with forebrain abnormalities
in glutamatergic and dopaminergic transmission (Bibb et al.,
2000; Cepeda et al., 2014), dysregulation of gene transcription
(Neueder and Bates, 2014), altered striatal enriched proteins
(e.g., PDE10A, STEP, Rhes; Subramaniam et al., 2009; Saavedra
et al., 2011; Leuti et al., 2013; Mealer et al., 2014; Fusco and
Giampà, 2015) and impaired neurotrophic support (e.g., BDNF-
TrkB pathway; Zuccato et al., 2001; Wild and Tabrizi, 2014).
Importantly, since the survival and maintenance of MSNs are
especially dependent on the BDNF-TrkB signaling pathway
(Ivkovic and Ehrlich, 1999; Baydyuk et al., 2011), reduced
neurotrophic support may underlie the early vulnerability of
MSNs to degeneration in HD.
Striatal MSNs express TrkB, the cognate receptor for brain
derived neurotrophic factor (BDNF), but do not produce BDNF.
They therefore rely on a supply from cortical, dopaminergic and
thalamic afferents for neurotrophic maintenance of survival and
phenotypic function (Altar et al., 1997; Sadikot et al., 2005). Low
BDNF protein levels are reported in postmortem striatal tissue
from HD patients at symptomatic disease stages (Ferrer et al.,
2000; Zuccato et al., 2008), however, it is not clear whether this
is associated with early neurtrophic deficiencies for MSNs or,
rather, a consequence of late stage cortical and striatal neuron
atrophy. Cellular models show that BDNF transcription and
transport can be impaired by overexpression or knock-in of
mhtt (Zuccato et al., 2001; Gauthier et al., 2004). Accordingly,
in vivo deficits of striatal BDNF levels are shown to correlate
with reduced cortical BDNF mRNA expression in some studies
of Q175 knock-in and YAC72 transgenic HD mouse models
(Zuccato et al., 2001; Ma et al., 2015). In contrast, evidence of
normal striatal BDNF levels at early and intermediate disease
stages in these (Seo et al., 2008; Plotkin et al., 2014) and other HD
mouse models (Pang et al., 2006; Potenza et al., 2007; Traficante
et al., 2007; Seo et al., 2008; Cepeda et al., 2010; Bobrowska et al.,
2011) argues that defects further downstream may underlie early
deficiencies in neurotrophic support for MSNs in HD.
BDNF neurotrophic support of MSNs is mediated by
full-length (fl) TrkB, a member of the neurotrophic tyrosine
receptor kinase family, that activates cytosolic signaling cascades
that promote survival and maintain neurochemical and
morphological properties. Low striatal fl-TrkB protein levels
are reported in postmortem tissue from HD patients at late
disease stages (Ginés et al., 2006; Brito et al., 2013). Studies
on HD mouse models have demonstrated varying degrees of
striatal TrkB deficits. Normal levels are reported at early disease
stages in knock-in Q175 (Smith et al., 2014; Ma et al., 2015)
and transgenic R6/1, R6/2, BACHD and D9 mice (Brown et al.,
2008; Gharami et al., 2008; Martire et al., 2010; Brito et al., 2013;
Plotkin et al., 2014), while deficits are reported at early stages
in knock-in HdhQ111 mice and later stages in R6/1 mice (Brito
et al., 2013). As an important caveat, observations at later stages
may be confounded by loss of volume or number of striatal
neurons as disease progresses (Stack et al., 2005; Samadi et al.,
2013). On the other hand, normal TrkB levels observed at early
stages may not necessarily reflect normal receptor function. For
example, defects in transport and scaffolding proteins associated
with TrkB signal transduction down the Erk1/2 pathway are
demonstrated inmhtt knock-in STHdhQ111 cells and HdhQ111
striatal cultures independent of changes in TrkB expression
(Ginés et al., 2010; Liot et al., 2013). The variability of reports on
TrkB expression and signaling in HD models may be attributed
in part to suboptimal tissue preservation and also fundamental
differences in cellular and mouse models. Examining TrkB
receptor expression in a well-characterized transgenic mhtt
model and further characterizing BDNF functional activation of
TrkB signaling in primary striatal cultures derived from the same
model may better define which defects occur in the BDNF-TrkB
pathway and how this affects neurotrophic support of MSNs at
early disease stages of HD.
We determined whether a primary defect in fl-TrkB
expression or signaling underlies reduced trophic support of
striatal neurons at an early stage in the R6/2 mouse model
of HD. The R6/2 mouse carries a 5′ end of exon 1 of
mutant human HTT transgene with expanded CAG repeats that
produces an N-terminalmhtt fragment protein. The R6/2 mouse
exhibits HD-like locomotor disorder and striatal pathology that
is accelerated relative to other genetic mouse models of HD
(Mangiarini et al., 1996; Menalled et al., 2009; Samadi et al.,
2013). Our assays on presymptomatic R6/2 mice indicated
that striatal morphology and protein levels of BDNF and fl-
TrkB are normal but levels of activated phospho-TrkB are
reduced compared to WT mice. Possible defective BDNF-
TrkB signaling was therefore further investigated in vitro using
primary striatal neuron cultures derived from R6/2 mice. We
found that the normal trophic effects of BDNF on striatal
neurons were attenuated in R6/2 cultures. Moreover, this was
associated with impaired BDNF-mediated activation of phospho-
TrkB despite normal expression of fl-TrkB in R6/2 cultures.
Finally, downstream activation of Erk1/2 was also impaired
in R6/2 cultures. Together these findings suggest that an
early impairment of TrkB activation and downstream signaling
underlies reduced trophic support of striatal neurons in HD.
MATERIALS AND METHODS
Animals
Wildtype (WT) B6CBA males were bred with female mice
that had received ovarian transplants from R6/2 females, which
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carry exon-1 of a human mutant HTT transgene with 120–130
CAG repeats (The Jackson Laboratory, MA, USA). Animal
procedures were in accordance with the Canadian Council
on Animal Care guidelines for ethical use and welfare of
animals in research, as administered by the McGill University
Animal Care Committee. R6/2-ovarian transplanted females
were mated with WT males to obtain littermate pups of
both genotypes. Tail-tip samples from pups were used for
PCR genotyping, and CAG repeat size (125 ± 5 repeats)
was verified. Littermates of both sexes were used at either
at postnatal day (P) 28–35 for striatal morphology and
protein assays, or at P1 for primary striatal neuron culture
assays.
Tissue Preparation for Striatal Stereology
and Protein Assays
Littermate adolescent pups (P28–35) were sacrificed by
decapitation for protein assays or by deep anesthesia with
phenobarbital and transcardial perfusion (0.9% heparinized
saline followed by PFA fixation- 4% paraformaldehyde in
0.1 M phosphate buffer, pH 7.4) for stereology. Brains for
stereological analysis were cryoprotected and subsequently
sectioned at 40 µm in the coronal plane then processed
for Nissl-staining (as previously described in detail, Samadi
et al., 2013). The neostriatum was delineated according to
defined boundaries (Sadikot and Sasseville, 1997) using a
stereotaxic atlas of the mouse brain (Franklin and Paxinos,
2008). The optical fractionator or nucleator were used as
stereology probes to obtain unbiased estimates of the total
number of neurons or cell size, respectively, for individual
animals and the results were averaged according to genotype
(as detailed in our previous work, Luk et al., 2003; Rymar et al.,
2004). For protein analysis, unperfused brains were dissected
into −80◦C isopentane. Atlas defined (Franklin and Paxinos,
2008) dorsolateral striatum tissue samples were obtained using
a 1 × 1.5 mm cylindrical micro-punch (Stoelting, IL, USA).
Striatal punches were lysed in 60 µL of RIPA buffer containing
protease and phosphatase inhibitors and assessed by western
blot (see below).
Primary Striatal Cultures
Previous studies characterizing the viability and phenotype
of striatal cultures indicate higher neuronal survival in B27-
compared to N2-supplemented neurobasal media (NBS; Brewer,
1995; Ivkovic and Ehrlich, 1999). N2 lacks vitamin A and free
radical scavenging enzymes: catalase, glutathione and superoxide
dismutase that are known trophic components of B27 (Ivkovic
and Ehrlich, 1999). Therefore our striatal culture assays were
done in N2-NBS, which minimizes confounding trophic effects
of B27. Postnatal day 1 (P1) striatal tissue from individual
pups was processed into parallel sister culture wells on poly-
lysine coated 96- or 6-well plates (BD Inc., ON, Canada).
Using microscissors and a dissecting microscope, striatal tissue
was dissected into ice-cold B27-Hibernate-A media (Invitrogen,
ON, Canada), digested with Tryp-LE and finally dissociated
in B27-NBS media (Invitrogen). Dissociated cells were plated
at low density (400 cells/mm2; 96-well poly-D-lysine coated
plates) or high density (obtain sufficient protein concentrations
for western blot assays, 1000 cells/mm2; 6-well poly-D-lysine
coated plates) and allowed to attach for 24 h in B27-NBS. After
1 day in vitro (DIV) the low density cultures were switched into
N2-NBS with vehicle (PBS) or BDNF (2, 10, 50 or 100 ng/mL)
and grown to 7 DIV, and finally used for immunofluorescence
cell counting assays. High density cultures were switched to
N2-NBS and grown to 3 DIV and used for protein quantification
assays.
Immunofluorescence Staining
BDNF effects on neuronal viability and phenotype in WT and
R6/2 cultures were assessed by immunofluorescence staining
for neurochemical markers of various cellular subpopulations.
On a single 96 well plate, sister wells (24 wells) from individual
pups (at least one WT and one R6/2 pup per plate) were
divided into four dose groups: 0, 2, 10 and 50 ng/mL BDNF
in N2-NBS media. Media containing the different BDNF
doses was replenished every 3 days. After 7 DIV, wells were
fixed with 4% paraformaldehyde buffer (4% paraformaldehyde
in 0.1 M phosphate buffer, pH 7.4), then blocked in 4%
BSA-PBS. The total cell population was labeled using the
nuclear stain DAPI (1:1000; Roche Inc, QC, Canada). The
neuronal population was co-labeled for β-III-tubulin (Tuj1
antibody, 1:3000; Covance, NJ, USA). Alexa-564 goat anti-rabbit
antibody was used for secondary fluorescent conjugation (1:1000;
Invitrogen). The apoptotic cell population was labeled using a
TUNEL staining kit (Roche Inc.). Other sets of cultures were
similarly plated and immumostained for makers of other cellular
subpopulations: striatal neuron markers- mouse anti-MAP2
(1:5000; Sigma Aldrich, ON, Canada) and rabbit anti-DARPP-32
(1:500; Millipore, MA, USA); mitotic progenitors- rabbit Ki67
(1:1000; Millipore). Fluorescence images were acquired for
each culture well at 16 predefined sites (10× objective,
XCD microscope; Molecular Devices, PA, USA). MetaXpress
software (Molecular Devices) was used to delineate and count
various immuno-labeled cell populations. The densities and
proportions (relative to total DAPI+ cell density) of each
labeled population was calculated per well, then averaged
according to treatment group and reported with standard
errors.
Western Blotting
Protein lysates were made from striatal tissue punches
(see above) or primary striatal cultures from individual WT
and R6/2 animals. Primary striatal cultures (see above) were
grown in N2-NBS for 48 h and then acutely exposed to control
(0 ng/ml; 20 min) or BDNF (100 ng/ml; 20 min) supplemented
media. Cultures were washed with PBS and total-protein
lysates were obtained in RIPA buffer containing protease and
phosphatase inhibitors and assessed by standard western blot
methods (Luk and Sadikot, 2004). Equivalent volumes of lysate
from WT and R6/2 tissue punches (∼20 mg of total protein)
or from cultures (∼2 mg of total protein) were ran in parallel
on 4–15% gradient gels for SDS-PAGE. Recombinant BDNF
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protein (PeproTech, NJ, USA) was also run in parallel as
a marker for the migration of endogenous BDNF at 14 kD
(Fawcett et al., 1997). Nitrosecellulose blots were blocked with
2.5% BSA-TBST and then probed with antibodies for total
TrkB (1:1000; Cell Signaling Technologies, MA, USA, #4603),
Erk1/2 (1:1500; CST, #9102), DARPP-32 (1:2000; Millipore,
#ab1656) and β-III-tubulin (1:10,000; Covance, #PRB435).
Replicate blots were generated in parallel and probed for
activated signaling proteins phospho-TrkB (Tyr704; 1:500; Santa
Cruz, CA, USA, #sc135645), phospho-Erk1/2 (Thr202/204;
1:2000; CST, #9106) and β-III-tubulin. Immunoblots were
labeled with secondary HRP-conjugated antibodies (goat
anti-rabbit or-mouse; 1:10,000; Millipore) and developed by
ECL (Pierce, IL, USA) and exposure on X-ray film (VWR,
ON, Canada). Films were scanned on a flatbed scanner with
backlighting. Image-J (NIH software, version 1.47) was used
for optical density (OD) quantification of each protein band.
Relative protein levels were derived by normalizing the OD of
the specific band to that of the β-III-tubulin (Tuj1) band in the
same lane, thereby controlling for any effect of unequal total
neuronal protein concentrations between lanes. Normalization
of phospho-proteins to their total unphosphorylated forms
yielded similar results as normalization to β-III-tubulin (data
not shown).
Statistical Analysis
Stereology and protein assays were done on brains of individual
WT (n > 3) and R6/2 (n > 3) mice and the data were averaged
according to genotype and reported as mean ± standard error
(SE). Mean data were compared for significant differences
(p< 0.05) using the Student’s t-test. Immunofluorescence assays
of BDNF dose-effects were done on parallel sister cultures (>16
culture wells/individual animal) derived from individual WT
(n > 3) and R6/2 (n > 3) mice. Data were grouped according
to genotype and BDNF dose (control, 2, 10, 50 ng/mL) and
reported as mean ± SE. ANOVA was used to determine the
main effects of genotype and drug, and posthoc Fisher-LSD
comparisons were done to determine significant differences
between genotypes at each dose. Protein assays of the effect of
BDNF on parallel sister cultures (2 culture wells/animal/2 drug
doses) that were derived from individual WT (n = 6) and R6/2
(n = 5) mice. Data were grouped according to genotype and
BDNF dose (control or 100 ng/mL) and reported as mean ± SE.
Mean data were compared between genotype groups at each drug
dose for significant differences (p < 0.05) using the Student’s
t-test.
RESULTS
Normal Morphology of Striatum in Young
R6/2 Mice
Unbiased stereology (Figures 1A,B) was used to determine
whether R6/2 mice exhibited striatal morphological changes at
a young age (P28–35) associated with a presymptomatic disease
stage (Samadi et al., 2013). The estimated total number of
neurons in the striatum was similar in WT and R6/2 mice
(1,144,207 ± 55,809 vs. 1,333,955 ± 55,522 cells, respectively;
p > 0.05). The cross-sectional area of striatal neurons was also
similar in WT and R6/2 mice (50.3 ± 2.0 vs. 52.6 ± 0.9 µm2,
respectively; p > 0.05). Moreover, the total striatal volume was
similar in WT and R6/2 mice (7.72 ± 0.28 vs. 7.67 ± 0.43 mm3,
respectively; p> 0.05).
Reduced Phospho-TrkB Levels in the
Striatum of Young R6/2 Mice
Western blot analysis of striatal tissue punches from young
(P28–35) R6/2 mice were assessed for alterations in components
of the BDNF-TrkB pathway. Striatal BDNF and fl-TrkB levels
were found to be similar in R6/2 and WT mice (Figures 1C,D).
Levels of truncated-TrkB (95 kDa; Figure 1C) were also similar
in R6/2 and WT mice (data not shown). However, levels
of activated phospho-TrkB were lower in R6/2 compared to
WT mice (Figures 1C,D). Since activation of phospho-TrkB
signaling regulates expression of the dopamine and cAMP
regulated neuronal phosphoprotein 32 kDa (DARPP-32; an
MSN-specific protein; Ivkovic and Ehrlich, 1999), we also found
that striatal DARPP-32 levels were low in young R6/2 mice
(Figures 1C,D).
Normal Basal Viability and Neuronal
Phenotype of R6/2 Striatal Cultures
Sister cultures (n = 19/genotype group) derived from the striatum
of individual WT (n = 4) and R6/2 (n = 4) littermate mice were
first assessed for differences in basal cell survival and neuronal
phenotype at 7 DIV in unsupplemented media. Previous studies
using similar minimal media conditions observe that striatal
cultures exhibit a majority population of neurons and a very
small population of non-neuronal cells (Mizuno et al., 1994;
Nakao et al., 1994; Ventimiglia et al., 1995). Counts of DAPI+
staining, a DNA label that identifies all cell nuclei in culture,
revealed that total cell density was similar in WT and R6/2
cultures (211 ± 22 and 208 ± 14 cells/mm2, respectively;
Figures 2A,B) after 7 DIV in basal media. Concurrently,
MAP2+ staining (microtubule associated protein 2; a neuron-
specific cytoskeletal protein) indicated a similar sized population
of neuronal cells in WT and R6/2 cultures (100 ± 14 and
103 ± 7 cells/mm2, respectively; Figures 2A,B). Furthermore,
DARPP-32+ staining indicated a similar sized population of
MSN-like cells in WT and R6/2 cultures after 7 DIV in basal
media (40± 8 and 40± 5 cells/mm2, respectively; Figures 2A,B).
These results are in line with other studies using striatal cultures
derived from newborn WT (Ivkovic and Ehrlich, 1999) and
R6/2 mice (Petersén et al., 2001), which typically exhibit a
small population of DARP-32+ neurons (1–25% of total cells in
culture) due in part to striatal tissue dissection at P1 prior to
the postnatal developmental period of neurotrophin expression
(Fryer et al., 1996; Sadikot et al., 2005) and MSN differentiation
(Ivkovic et al., 1997).
Other cellular markers of non-neuronal cells were assessed
in separate sets of cultures. GFAP+ staining (glial fibrillary
acidic protein) demonstrated a minor population of astrocytes
in cultures from both genotypes. The size of the astrocyte
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FIGURE 1 | Young R6/2 mice exhibit normal striatal morphology but reduced phospho-TrkB protein levels. (A) Stereological estimates of total volume of
the neostriatum, number of striatal neurons, and cross-sectional area of striatal neurons in WT (n = 3) and R6/2 (n = 3) mice. (B) Photomicrographs of Nissl-stained
coronal sections of striatum from a WT and R6/2 mouse. Scale bar = 1500 µm. (C) Sample immunoblots of proteins in striatal tissue lysates from different WT and
R6/2 mice. (D) BDNF and full-length (fl) TrkB levels were similar in WT (n = 7) and R6/2 (n = 6) striatal tissue. Significantly lower levels of phospho-TrkB and
DARPP-32 are noted in R6/2 compared to WT striatal tissue. Relative protein levels were determined by normalization to the neuronal specific cytoskeleton protein
β-III-tubulin. Unpaired Student’s t-test: ∗p < 0.05, ∗∗p < 0.001.
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FIGURE 2 | Similar neuronal populations in WT and R6/2 striatal cultures in basal media conditions. (A) Co-immunofluorescence images of DAPI+ (blue),
MAP2+ (green) and DARPP-32+ (red) stained cells in WT (top panels) and R6/2 (bottom panels) cultures after 7 day in vitro (DIV) in unsupplemented media. Scale
bar = 100 µm. (B) Average density of cells expressing neuronal (MAP2+) and striatal (DARPP-32+) phenotype in WT (n = 19) and R6/2 (n = 19) cultures.
population was similar in WT and R6/2 cultures (2.1 ± 0.3 and
1.5 ± 0.4%, respectively; n > 15). The mitotic cell population
was assessed using Ki67+ staining. The size of the mitotic cell
population was also similar in WT and R6/2 cultures (6.7 ± 0.3
and 7.1± 0.4%, respectively; n> 15).
BDNF Neurotrophic Effects are Attenuated
in R6/2 Striatal Cultures
To determine whether there is a primary defect in TrkB function
in HD striatum, sister cultures (n > 15/dose group) were
derived from the striatum of individual WT (n = 3) and R6/2
(n = 5) littermate mice and assessed for BDNF dose-effect
on neuronal survival. Previous studies have demonstrated that
BDNF, via activation of TrkB, mediates trophic effects on striatal
neurons in culture. For example, striatal cultures exposed to
BDNF (10–100 ng/mL; 7 DIV) exhibit greater neuronal survival
and MSN phenotype (e.g., DARPP-32 expression) compared
to untreated cultures (Mizuno et al., 1994; Nakao et al., 1995;
Ventimiglia et al., 1995).
The BDNF dose-effect (2–50 ng/mL; 7 DIV) on neuronal
survival was assessed by quantifying the cellular population
that was immunoreactive for β-III-tubulin, a neuron specific
cytoskeleton protein. There were significant main effects of
both BDNF dose and genotype on the population of neurons
in culture (Figures 3A,B; ANOVA: dose- F(3,167), p < 0.01);
genotype- F(1,167), p < 0.01). Fisher-LSD posthoc pairwise
comparisons within the WT genotype group indicated the
neuronal populations in the 2, 10 and 50 ng/mL dose groups were
larger (p < 0.05) than in the untreated WT group. In contrast,
comparisons within the R6/2 genotype group indicated that only
the 10 and 50 ng/mL dose groups had larger (p< 0.05) neuronal
populations than the untreated R6/2 group. Fisher-LSD posthoc
pairwise comparisons within the control dose (0 ng/mL) group
did not detect any differences between WT vs. R6/2 cultures.
However, within the 10 and 50 ng/mL dose groups, the neuronal
population was larger (p < 0.05) in WT compared to R6/2
cultures (e.g., 50 ng/mL: 33.4 ± 0.7 vs. 27.9 ± 1.1%, respectively;
Figures 3A,B). Notably, BDNF (50 ng/mL) treatment lead to
a ∼34% increase in the neuronal population in WT cultures, in
contrast to a ∼21% increase in R6/2 cultures. Striatal neurons in
R6/2 cultures were therefore resistant to BDNF survival effects
compared to neurons in WT cultures.
The BDNF dose-effect on apoptosis was assessed by
quantifying the population of TUNEL+ stained cells. There were
significant main effects of both BDNF dose and genotype on the
population of TUNEL+ cells in culture (Figures 3A,C; ANOVA:
dose- F(3,167), p < 0.01; genotype- F(1,167), p < 0.01). Fisher-
LSD posthoc pairwise comparisons within the WT genotype
group indicated the TUNEL+ populations in the 10 and
50 ng/mL dose groups was smaller than in the untreated WT
group. Also, comparisons within the R6/2 group indicated the
TUNEL+ populations in the 10 and 50 ng/mL dose groups
were lower than in the untreated R6/2 group. Fisher-LSD
posthoc pairwise comparisons between the WT and R6/2
genotypes at the 10 or 50 ng/mL doses indicated that the
TUNEL+ populations in WT cultures were lower than in
R6/2 cultures (e.g., 50 ng/mL: 37.4 ± 1.5 vs. 45.5 ± 1.6%,
respectively; p < 0.05). BDNF is therefore less effective in
rescuing cells from apoptosis in R6/2 cultures compared to WT
cultures.
BDNF-TrkB signaling is well known to promote expression
of DARPP-32 (Nakao et al., 1995; Ivkovic et al., 1997), a
striatal-enriched protein essential for proper function of striatal
MSNs (Bibb et al., 2000). Therefore BDNF-TrkB function
was assessed by comparing the DARPP-32+ populations in
WT and R6/2 cultures that were exposed to either vehicle or
BDNF supplemented media. In vehicle supplemented media the
DARPP-32+ population in WT and R6/2 cultures was similar
(14.2 ± 1.3 and 15.5 ± 1.0%, respectively; Figure 3D). In BDNF
(50 ng/mL) supplemented media the DARPP-32+ population
was larger in WT compared to R6/2 cultures (25.5 ± 1.7
and 21.7 ± 1.7%, respectively; p < 0.05; Figure 3D). Notably,
BDNF treatment lead to a ∼76% increase in the DARPP-32+
population in WT cultures in contrast to a ∼41% increase
in R6/2 cultures. These results indicate that R6/2 striatal
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FIGURE 3 | BDNF neurotrophic effects are attenuated in R6/2 striatal cultures. (A) Co-immunofluorescence images of DAPI+ (blue), β-III-tubulin+ (green) and
TUNEL+ (red) stained cells after 7 DIV in media supplemented with 50 ng/mL BDNF. BDNF promoted the survival of β-III-tubulin+ neurons and attenuated the
number of dying TUNEL+ cells in WT cultures (top panels) to a greater extent than in R6/2 cultures (bottom panels). Scale bar = 50 µm. (B) BDNF dose-effect on the
β-III-tubulin+ neuronal population in WT (n = 15–18/dose) and R6/2 (n = 25–29/dose) cultures. ANOVA main effects: dose- F(3,167), p < 0.01; genotype- F(1,167),
p < 0.01; Fisher-LSD comparisons: ∗p < 0.05. (C) BDNF dose-effect on TUNEL+ dying cell population in WT (n = 15–18/dose) and R6/2 (n = 25–29/dose) cultures.
ANOVA main effects: dose- F(3,167), p < 0.01; genotype- F(1,167), p < 0.01; Fisher-LSD comparisons: ∗p < 0.05. (D) BDNF effect on DARPP-32+ striatal neuron
population in WT (n = 19) and R6/2 (n = 20) cultures. Unpaired Student’s t-test: ∗p < 0.05.
cultures are less sensitive to BDNF-stimulated expression of
DARPP-32.
BDNF-TrkB Signal Transduction is
Impaired in R6/2 Striatal Cultures
We determined whether activation of the BDNF-TrkB signaling
cascade is impaired in primary striatal cultures from R6/2 mice.
Cultures grown for 48 h in N2-basal media were acutely (20 min)
exposed to control or BDNF-supplemented media- a high dose
of 100 ng/mL BDNF was used to maximize the detection
of activated phospho-TrkB. In control conditions (saline) fl-
TrkB (Figures 4A,B) and phospho-TrkB (Figures 4A,D) levels
were similar in WT and R6/2 cultures. Exposure to BDNF
elevated phospho-TrkB levels over control conditions in both
WT and R6/2 cultures (Figures 4A,D). Importantly, BDNF
yielded higher phospho-TrkB levels in WT compared to R6/2
cultures, indicating that BDNF-induced activation of TrkB is
blunted in R6/2 cultures.
Since previous studies in cellular and animal models
of HD have reported defects in BDNF-mediated activation of
TrkB-Erk1/2 rather than the-Akt pathway (Ginés et al., 2010;
Brito et al., 2013), we assessed the levels of activated phospho-
Erk1/2 to characterize transduction downstream of TrkB in R6/2
cultures. In control conditions total Erk1/2 and phospho-Erk1/2
levels were similar in WT and R6/2 cultures (Figures 4A,C).
Acute exposure to BDNF increased phospho-Erk1/2 levels over
control conditions in bothWT and R6/2 cultures (Figures 4A,E).
However, BDNF yielded higher phospho-Erk1/2 levels in
WT compared to R6/2 cultures, indicating that TrkB signal
transduction down the Erk1/2 pathway is attenuated in R6/2
cultures.
DISCUSSION
The primary neuropathological feature of Huntington disease
(HD) is an early and prominent degeneration of MSNs, the
principal projection neurons of the striatum. Various gain- and
loss-of-function mechanisms are proposed to underlie MSN
degeneration in HD, including excitotoxicity, metabolic failure,
altered protein expression and impaired signal transduction
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FIGURE 4 | TrkB activation and signal transduction is impaired in R6/2
striatal cultures. (A) Sample immunoblots of TrkB and Erk1/2 signaling
proteins from WT and R6/2 cultures after exposure to control (−) or
100 ng/mL BDNF (+) supplemented media. (B) fl-TrkB and (C) Erk1/2 levels
are similar in control treated WT (n = 6) and R6/2 (n = 5) cultures. BDNF
treatment did not change the levels of these proteins. (D) p-TrkB and
(E) p-Erk1/2 levels after treatment with saline or BDNF. BDNF treatment
increased p-TrkB and p-Erk1/2 levels to a greater extent in WT (n = 6)
compared to R6/2 (n = 5) cultures. Relative protein levels were determined by
normalization to the neuronal specific cytoskeleton protein β-tubulin. Unpaired
Student’s t-test ∗p < 0.05.
(Harjes and Wanker, 2003; Roze et al., 2011). Gain-of-function
effects of mhtt are effectively assessed in the R6/2 mouse
model of HD, which expresses an N-terminal fragment of
mhtt in the presence of normal Htt protein and exhibits a
phenotype of early striatal MSN degeneration and locomotor
dysfunction (Mangiarini et al., 1996; Stack et al., 2007; Samadi
et al., 2013). Studies in cellular and animal models of HD
suggest various defects in the BDNF-TrkB signaling pathway
may lead to reduced neurotrophic support of MSNs, but
the precise nature and timing of these can vary depending
on the model. The present study assessed striatal tissue and
primary cultures from young R6/2 mice to determine whether
early defects in the BDNF-TrkB pathway underlies reduced
survival and maintenance of striatal MSNs. The main findings
show striatal levels of phospho-TrkB are low in young R6/2
mice prior to any significant neuronal degeneration or loss of
BDNF in the striatum. Additionally, in vitro experiments on
R6/2 striatal cultures show that BDNF activation of phospho-
TrkB and the Erk1/2 pathway is impaired in association
with a reduction in BDNF-mediated neurotrophic effects
on MSNs.
Studies on human HD tissue samples and YAC72, BACHD
and R6/2 mice (Zuccato et al., 2001, 2005, 2008; Gray et al.,
2008) show that cortical BDNF mRNA expression is impaired,
suggesting this reduces BDNF supply to the striatum in these
HD models. Conflicting studies report that cortical BDNF
expression is normal in symptomatic BACHD mice (Plotkin
et al., 2014) and human HD tissue samples (Ferrer et al.,
2000; Gauthier et al., 2004), arguing that other downstream
defects contribute to reduced BDNF neurotrophic support,
such as impaired axonal transport machinery (Gauthier et al.,
2004) or altered TrkB receptor signal transduction (Plotkin
et al., 2014). Evidence of normal striatal BDNF levels at late
disease stages in YAC72, R6/2 and other mouse models (Ginés
et al., 2006; Pang et al., 2006; Seo et al., 2008; Cepeda et al.,
2010; Bobrowska et al., 2011) further argues that impaired
afferent BDNF supply alone may not account for impaired
neurotrophic support. The current study extends evidence
of normal striatal BDNF levels in young adult R6/2 mice,
suggesting. downstream defects in TrkB receptor transduction
may underlie early deficits in neurotrophic support of MSNs in
this HD model.
Full-length TrkB receptors, whose expression is increased in
the striatum during the perinatal period (Fryer et al., 1996),
mediate BDNF’s neurotrophic effects on MSN survival and
phenotypic maintenance in the developing and adult striatum
(Alcántara et al., 1997; Ivkovic et al., 1997; Baydyuk et al.,
2011). For example, germline or regionally targeted knockout of
striatal fl-TrkB (Baydyuk et al., 2011; Li et al., 2012) attenuates
the developmental rise of striatal DARPP-32 expression that
occurs during the first postnatal month in rodents (Ehrlich
et al., 1990). Moreover, ongoing TrkB-mediated regulation of
striatal DARPP-32 expression is demonstrated in post-weanling
mice (P24–31) that are exposed to cocaine (Niculescu et al.,
2008). The R6/2 mhtt transgene is driven by a promotor
analogous to the endogenous Htt gene, and the expression of
Htt in CNS neurons increases during the first few postnatal
weeks (Bhide et al., 1996). We assessed components of the
TrkB pathway in adult R6/2 mice and primary cultures derived
from postnatal striatum. TrkB expression is reduced in knock-
in mhtt STHdhQ111 immortalized cells (Ginés et al., 2010).
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Furthermore, reduced levels of total TrkB are demonstrated in
the striatum of young knock-in HdhQ111 mice (Ginés et al.,
2006; Brito et al., 2013). This model retains a normal lifespan
and exhibits only a subtle HD-phenotype of striatal degeneration.
In contrast, several other mhtt knock-in and transgenic mouse
models that exhibit clear striatal degeneration, show normal
striatal total TrkB levels at both early and late disease stages
(Brown et al., 2008; Gharami et al., 2008; Martire et al., 2010;
Xie et al., 2010; Simmons et al., 2013; Plotkin et al., 2014;
Smith et al., 2014; Ma et al., 2015). The present findings in
young R6/2 mice show that striatal total TrkB levels are normal
at a stage prior to striatal atrophy and neuronal loss. We
now provide evidence that striatal levels of activated phospho-
TrkB are reduced at this early stage when BDNF levels are
normal. Striatal DARPP-32 levels are also reduced at this early
stage in R6/2 mice. Indeed DARPP-32 expression is regulated
by BDNF-TrkB signaling independent of neuronal survival
(Ivkovic and Ehrlich, 1999). These findings suggest impaired
activation of phospho-TrkB signaling is associated with reduced
neurotrophic maintenance of MSN-phenotype at an early age in
R6/2 mice.
Reduced BDNF-TrkB neurotrophic support of MSNs is
further demonstrated in our experiments on R6/2 primary
striatal cultures. In keeping with previous studies using primary
striatal cultures derived from HD mice (Petersén et al., 2001;
Liot et al., 2013), the basal neuron survival of R6/2 cultures
was similar to WT cultures when grown in unsupplemented
media. We now show that whereas BDNF-supplemented media
promotes neuronal survival by up to ∼34% in WT cultures,
this effect is attenuated in R6/2 cultures to only ∼21%. These
in vitro findings suggest that MSNs in R6/2 mice are relatively
resistant to pro-survival effects of BDNF. Additionally, while
BDNF increases the population of DARPP-32 expressing cells
by up to ∼76% in WT cultures, this effect is attenuated
in R6/2 cultures to only ∼41%. Notably the BDNF effect
on neuronal survival does not completely account for its
greater effect on DARPP-32 expression, which is in line with
studies suggesting parallel roles of BDNF in promoting survival
(Nakao et al., 1995; Baydyuk et al., 2011) and maintaining
phenotypic properties of MSNs (Ivkovic and Ehrlich, 1999).
These in vitro findings indicate that BDNF maintenance
of MSN phenotype is impaired in R6/2 mice. This is in
keeping with our in vivo results showing an early decline
of striatal DARPP-32 expression in young R6/2 mice, even
in the presence of normal BDNF levels and total neuronal
population.
BDNF-TrkB signal transduction involves several pathways,
including Erk1/2, phosphoinositol-3 kinase (PI3K) and
phospolipase C-gamma (PLCg; Reichardt, 2006). TrkB-mediated
neuronal survival and maintenance of a wide variety of CNS
neurons is dependent on the Erk1/2 pathway (Atwal et al.,
2000; Cheng et al., 2002; Barnabe-Heider and Miller, 2003),
and is a major pathway that is necessary for BDNF-dependent
transcription and phenotypic maintenance of striatal neurons
(Gokce et al., 2009). Studies in cellular models indicate that
mhtt expression can elevate activation of Erk1/2 signaling
(Apostol et al., 2006), which may be part of a pro-survival
response or associated with dysfunction of other signaling
pathways (Ribeiro et al., 2010; Bodai and Marsh, 2012).
Significant variability is noted in different studies examining
striatal Erk activation in transgenic or knock-in models of HD.
Indeed some studies using R6/2 mice demonstrate normal
striatal phospho-Erk1/2 levels at 8 weeks, and elevated levels
are noted only at late stages (Liévens et al., 2002; Roze et al.,
2008), possibly related to stress responses or dysfunctional
transcriptional feedback (Liévens et al., 2002; Roze et al.,
2008; Bodai and Marsh, 2012). In contrast other studies in
R6/2 mice report reduced striatal phospho-Erk1/2 levels at
8 and 12 weeks (Fusco et al., 2012; Simmons et al., 2013).
Importantly, TrkB-mediated activation of the Erk1/2 pathway
is impaired in other cellular and mouse models of HD. For
example mhtt knock-in STHdhQ111 cell lines or HdhQ111
mouse-derived primary cultures exhibit attenuated BDNF-
mediated activation of phospho-Erk1/2 (Ginés et al., 2010;
Liot et al., 2013). It was suggested that impaired expression or
transport of TrkB may account for attenuated BDNF-mediated
Erk1/2 signaling in these models. The final level of Erk1/2
activation is likely dependent on multiple factors altered in
HD striatum (e.g., dopamine, glutamate signaling; Gardoni
and Bellone, 2015), which act in concert with alterations
related to the BDNF-TrkB survival pathway. We now provide
evidence that basal levels of TrkB, phospho-TrkB, Erk1/2 and
phospho-Erk1/2 are normal in R6/2 striatal cultures. However,
BDNF activation of phospho-TrkB and phospho-Erk1/2 is
attenuated, and is associated with reduced BDNF-mediated
survival and phenotypic maintenance of R6/2 cultures. These
results are consistent with the observed deficiencies in striatal
TrkB activation and phenotypic maintenance in the presence of
normal BDNF levels in early presymptomatic R6/2 mice.
The cause of striatal degeneration in HD is likely related to
multiple cell autonomous and non-autonomous mechanisms,
including excitotoxicity in conjunction with impaired
neurotrophic support (Harjes and Wanker, 2003; Milnerwood
and Raymond, 2010; Baydyuk and Xu, 2014). Since the striatum
does not produce BDNF and depends on supply from cortical,
thalamic and midbrain afferents (Altar et al., 1997; Sadikot
et al., 2005), anterograde neurotrophic factor support may be
critical for striatal neurons in HD (Zuccato et al., 2005). The
present study demonstrates that striatal neurons from the R6/2
model of HD also exhibit a blunted trophic response to BDNF
that is associated with decreased activation of the TrkB-Erk1/2
signaling pathway. This work suggests neurotrophin-based
therapies for HD should address both the deficit in BDNF
supply (Bates et al., 2015) and the impaired signal transduction
from the TrkB receptor (Apostol et al., 2008; Simmons et al.,
2013). Further characterization of mhtt interactions with TrkB
signaling pathways may contribute to development of novel
targets for therapy in HD.
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